Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 25, 2011

View Archived Issues

Sunnybrook Health Sciences and sanofi-aventis to develop vasculotide

AR-42 displays potent antitumor effects in models of embryonal carcinoma

BMS-936558 shows promise in RCC and mCRPC in phase I trial

Combined GWAS meta-analysis reveals shared genetic risk loci for Crohn's disease and celiac disease

Epidermal growth factor receptor may be marker of progression of penile squamous cancer

CD151 antigen is a marker of prostate cancer recurrence after radical prostatectomy

Vertex reports clinical data on ivacaftor in cystic fibrosis

Enrollment complete in translational clinical study of Reolysin in metastatic colorectal cancer

Bayer and Onyx begin enrollment in phase III Nexavar trial in advanced breast cancer

Evolva demonstrates preclinical efficacy of EV-077 in influenza

FDA approves OraQuick HCV Rapid Antibody Test

Endpoints met in phase Ib trial of TransPharma's ViaDor-GLP-1 agonist in type 2 diabetes

Novo Nordisk submits BLA to FDA for rFXIII in FXIII deficiency

FDA approves label update for Onglyza

NPS Pharma gives product pipeline update

IRM discloses new inhibitors of tyrosine-protein kinase SYK

Merck & Co. discloses new inhibitors of HCV serine protease NS3

Takeda submits NDA to FDA for azilsartan medoxomil plus chlorthalidone

Pharmaxis launches Aridol test kit in U.S. for bronchial hyperresponsiveness

Novartis claims new inhibitors of cyclin-dependent kinase 9

NV Organon patents new glycoprotein hormone FSH receptor agonists

Salix provides update on Xifaxan sNDA for non-constipation-predominant IBS and IBS-related bloating

Ascendis Pharma divulges new prodrugs of pramipexole

Trevena begins phase II TRV-120027 trial in acute heart failure

Isis reports phase I data on C-reactive protein inhibitor ISIS-CRPRx

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
Deals and an M&A strengthen end-of-year numbers
BioWorld
Two large deals and an acquisition, totaling about $4.64 billion in all, are helping wrap up what’s turning out to be a strong year. Through the first 11 months...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
Radiopharm Theranostics’ RAD-101 meets brain metastases endpoints
BioWorld
Radiopharm Theranostics Ltd.’s radiotracer RAD-101 met the primary endpoint in 92% of patients in the phase IIb imaging trial in brain metastases, according to...